Navigation Links
Acorda's Ampyra Sustains High Levels of Interest Seven Months After Launch With Favorable Future Share Projections

EXTON, Pa., Dec. 13, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that on most metrics, perceptions of Acorda's Ampyra, the first FDA-approved product for the management of a multiple sclerosis (MS) symptom, have remained consistent or improved since earlier waves, including product awareness, interest, satisfaction, the managed care process and Acorda's patient support program. Compared to early in the launch, patient requests play a less impactful role in Ampyra uptake. With increased familiarity after seven months on the market, neurologists are gaining a clear picture of the discontinuation rates, responder rates and insurance dynamics associated with Ampyra.

The recently released third and final wave of the LaunchTrends®: Ampyra report series finds that about half of the surveyed neurologists had been detailed on Ampyra within the past month.  Those considered high prescribers of the brand recall dialogue related to reimbursement. While market share of Ampyra was not significantly different compared to the prior wave, the respondents report starting significantly more dalfampridine-naive patients on Ampyra compared to earlier waves. More than three-quarters of the surveyed neurologists currently prescribe Ampyra and projected market share increases for the brand are expected to come from both an expanded user base as well as increased use among current prescribers.

LaunchTrends®: Ampyra is a three wave syndicated report series designed to track the uptake of Acorda's Ampyra at one month, four months and seven months following its commercial availability. In the current wave of research, which measures Ampyra's market impact at seven month post-launch, BioTrends surveyed 76 neurologists and conducted qualitative interviews with a subset of 20 of the respondents in November 2010. BioTrends will continue to track the uptake of Ampyra in TreatmentTrends®: Multiple Sclerosis, a report series published quarterly in the U.S. and annually in the EU, which provides a comprehensive view of the current and anticipated future management of MS. BioTrends also recently released ChartTrends®: Multiple Sclerosis, a patient chart audit of over 1,000 MS patients assessing how MS patients are being managed with disease modifying agents as well as agents used in symptomatic conditions.  

About LaunchTrendsLaunchTrends assesses trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction.

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. ( provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, Inc.Decision Resources, Inc.Sharon Funk

Christopher Comfort404-223-2963


SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
2. Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004
3. Tocotrienols Shown to be Effective in Lowering Fat Levels in Blood
4. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
5. People at Intermediate Risk of Heart Disease With Elevated hsCRP Benefit From Statin Therapy Even if Cholesterol Levels are Normal
6. FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels
7. Single Dose of Proprietary Adult Stem Cells Regenerates Damaged Pancreas and Reduces Blood Glucose Levels in Diabetes
8. New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood
9. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
10. Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
11. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Post Your Comments:
(Date:11/30/2015)... , December 1, 2015 ... adds "Endometriosis - Pipeline Review, ... an overview on therapeutic pipeline of Endometriosis ... create effective counter strategies to gain competitive ... new targets and MOAs to produce first-in-class ...
(Date:11/30/2015)... 2015 ) ... Drugs Market 2015-2019" report to their offering. ... addition of the "Orphan Drugs Market 2015-2019" ... Research and Markets ( ) has announced ... 2015-2019" report to their offering. ...
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 01, 2015 , ... The Turks & Caicos Islands has enjoyed being in ... sites highlighting Caribbean destinations, has published five reasons to visit the Turks & Caicos. ... under chilly grey skies or worse, it's typically a balmy 80 degrees in the ...
(Date:11/30/2015)... MN (PRWEB) , ... December 01, 2015 , ... ... is the latest carrier to offer individual vision insurance plans on ... the unique ability to rate and review products, allowing consumers to compare, quote ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to research by ... require dental technicians to be certified or obtain continuing education. To increase awareness ... In Your Mouth?” campaign to inform dentists that the technicians they trust could ...
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair ... and follicular unit extraction. These techniques and procedures have been in use for many ... hair loss. While Dr. Parsa Mohebi, M.D. has utilized many of these methods over ...
(Date:11/30/2015)... ... November 30, 2015 , ... During the ... campaign to raise funds for its research, education, support, and advocacy efforts. The ... annual funding. , The Mesothelioma Applied Research Foundation, which also goes by Meso ...
Breaking Medicine News(10 mins):